Gemstone Biotherapeutics is looking to get a second treatment for wound care to the market.
The company licensed a product that is designed to specifically heal diabetic foot ulcers from Johns Hopkins University, said CEO George Davis. With the new addition to the portfolio, the Federal Hill-based company is looking to commercialize two products at once.
Davis said the company sees a big opportunity with the new technology, which was developed out of research led by Jeremy Walston and Peter Abadir in the Johns Hopkins School of Medicine.
The open sores that develop on the bottom of the foot affect about 15 percent of patients with diabetes, and can lead to amputations. The treatment that Gemstone licensed is a topical gel that reactivates a system of mitochondrial angiotensin receptors that weakens with age, and prohibits wounds from healing. It applies drugs that are currently used to treat hypertension to the wounds.
Read more at Technical.ly Baltimore
from http://baltimoretech.org/news/gemstone-biotherapeutics-adds-another-wound-healing-technology/
No comments:
Post a Comment